Zealand Pharma reported updated phase 1b results for its dapiglutide, a dual glucagon-like peptide-1 and peptide-2 receptor agonist, showing an average body weight reduction of 11.6% after 28 weeks with the higher dosing regimen. The trial enrolled primarily male patients without lifestyle interventions, with tolerability confirmed and no severe adverse events. The weight loss effect approaches that of leading once-weekly GLP-1 therapies and offers potential to address obesity-related comorbidities through its unique mechanism involving anti-inflammatory actions.